Advertisement

First trimester pregnancy-associated plasma protein-A and birth weight

  • Rebecca J. Baer
    Correspondence
    Corresponding author at: Department of Pediatrics, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. Tel.: +1 206 351 0850; fax: +1 510 412 1557.
    Affiliations
    Genetic Disease Screening Program, California Department of Public Health, 850 Marina Bay Parkway, Richmond, CA 94804, United States

    Department of Pediatrics, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States
    Search for articles by this author
  • Deirdre J. Lyell
    Affiliations
    Stanford University, Department of Obstetrics & Gynecology, 300 Pasteur Drive, Stanford, CA 94305, United States
    Search for articles by this author
  • Mary E. Norton
    Affiliations
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA 94143, United States
    Search for articles by this author
  • Robert J. Currier
    Affiliations
    Genetic Disease Screening Program, California Department of Public Health, 850 Marina Bay Parkway, Richmond, CA 94804, United States
    Search for articles by this author
  • Laura L. Jelliffe-Pawlowski
    Affiliations
    Genetic Disease Screening Program, California Department of Public Health, 850 Marina Bay Parkway, Richmond, CA 94804, United States

    Department of Epidemiology and Biostatistics, University of California School of Medicine, 550 16th Street, San Francisco, CA 94158, United States
    Search for articles by this author
Published:December 30, 2015DOI:https://doi.org/10.1016/j.ejogrb.2015.12.019

      Abstract

      Objective

      To evaluate first trimester pregnancy-associated plasma protein-A (PAPP-A) and birth weight percentile.

      Study design

      Included were women who underwent first trimester prenatal screening through the California Prenatal Screening Program with expected dates of delivery between August 2009 and December 2010, linked birth certificate and hospital discharge records, known birth weight, and no chromosomal abnormality (n = 134.105). PAPP-A results were reported as multiples of the median. The frequency of small or large for gestational age (SGA, ≤10%; LGA, ≥90%) versus appropriately grown for gestational age birth was examined by PAPP-A percentile. Patterns were studied by gestational age at delivery. Relative risks (RRs) and their 95% confidence intervals were adjusted for race/ethnicity.

      Results

      Women with PAPP-A ≤10th percentile and an infant born after 32 weeks were increasingly more likely to have an SGA infant (adjRRs 1.5–4.6) as the PAPP-A percentile declined, and were increasingly less like to have an LGA infant born at term (adjRRs 0.5–0.7) compared to women with PAPP-A measurement >10th to <90th percentile. PAPP-A ≥90th percentile was protective for SGA among infants born after 32 weeks gestation (adjRRs 0.3–0.7) and was associated with LGA among infants born at term (adjRRs 1.2–8.2).

      Conclusion

      Women with PAPP-A ≤10th percentile are more likely to have an SGA infant at all gestational ages. PAPP-A ≥90th percentile is protective against SGA and is associated with an increased risk of LGA for infants born after 32 weeks gestation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Pallotto E.K.
        • Kilbride H.W.
        Perinatal outcome and later implications of intrauterine growth restriction.
        Clin Obstet Gynecol. 2006; 49: 257-269
        • Lundgren E.M.
        • Tuvemo T.
        Effects of being born small for gestational age on long-term intellectual performance.
        Best Pract Res Clin Endocrinol Metab. 2008; 22: 477-488
        • de Bie H.M.
        • Oostrom K.J.
        • Delemarre-van de Waal H.A.
        Brain development, intelligence and cognitive outcome in children born small for gestational age.
        Horm Res Paediatr. 2010; 73: 6-14
        • Sheridan C.
        Intrauterine growth restriction – diagnosis and management.
        Aust Fam Phys. 2005; 34: 717-723
        • Berard J.
        • Dufour P.
        • Vinatier D.
        • et al.
        Fetal macrosomia: risk factors and outcome. A study of the outcome concerning 100 cases >4500 g.
        Eur J Obstet Gynecol Reprod Biol. 1998; 77: 51-59
        • Walsh J.M.
        • McAuliffe F.M.
        Prediction and prevention of the macrosomic fetus.
        Eur J Obstet Gynecol Reprod Biol. 2012; 162: 125-130
        • Currier R.
        • Wu N.
        • van Meter K.
        • Goldman S.
        • Lorey F.
        • Flessel M.
        Integrated and first trimester prenatal screening in California: program implementation and patient choice for follow-up services.
        Prenat Diagn. 2012; 32: 1077-1083
        • Dugoff L.
        • Hobbins J.C.
        • Malone F.D.
        • et al.
        First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
        Am J Obstet Gynecol. 2004; 191: 1446-1451
        • Jelliffe-Pawlowski L.L.
        • Shaw G.M.
        • Currier R.J.
        • et al.
        Association of early-preterm birth with abnormal levels of routinely collected first- and second-trimester biomarkers.
        Am J Obstet Gynecol. 2013; 208: 492-511
        • Jelliffe-Pawlowski L.L.
        • Baer R.J.
        • Currier R.J.
        • et al.
        Early-onset severe preeclampsia by first trimester pregnancy-associated plasma protein A and total human chorionic gonadotropin.
        Am J Perinatol. 2015; 32: 703-712
        • Peterson S.E.
        • Simhan H.N.
        First-trimester pregnancy-associated plasma protein A and subsequent abnormalities of fetal growth.
        Am J Obstet Gynecol. 2008; 198: e43-e45
        • Plasencia W.
        • Akolekar R.
        • Dagklis T.
        • Veduta A.
        • Nicolaides K.H.
        Placental volume at 11–13 weeks’ gestation in the prediction of birth weight percentile.
        Fetal Diagn Ther. 2011; 30: 23-28
        • Giudice I.
        • Benintende G.
        • Di Nicolo A.M.
        • et al.
        Correlation of neonatal weight with maternal serum levels of pregnancy-associated plasma protein-A during the first trimester of pregnancy: a retrospective study.
        J Perinat Med. 2015; 43: 227-232
        • Desai N.
        • Krantz D.
        • Roman A.
        • Fleischer A.
        • Boulis S.
        • Rochelson B.
        Elevated first trimester PAPP–a is associated with increased risk of placenta accreta.
        Prenat Diagn. 2014; 34: 159-162
        • Irwin J.C.
        • Suen L.F.
        • Martina N.A.
        • Mark S.P.
        • Giudice L.C.
        Role of the IGF system in trophoblast invasion and pre-eclampsia.
        Hum Reprod. 1999; 14: 90-96
        • Rizzo G.
        • Capponi A.
        • Pietrolucci M.E.
        • Capece A.
        • Arduini D.
        First-trimester placental volume and vascularization measured by 3-dimensional power Doppler sonography in pregnancies with low serum pregnancy-associated plasma protein a levels.
        J Ultrasound Med. 2009; 28: 1615-1622
        • Sahraravand M.
        • Jarvela I.Y.
        • Laitinen P.
        • Tekay A.H.
        • Ryynanen M.
        The secretion of PAPP-A, ADAM12, and PP13 correlates with the size of the placenta for the first month of pregnancy.
        Placenta. 2011; 32: 999-1003
        • Kazerouni N.N.
        • Currier R.J.
        • Flessel M.
        • et al.
        Detection rate of quadruple-marker screening determined by clinical follow-up and registry data in the statewide California program, July 2007 to February 2009.
        Prenat Diagn. 2011; 31: 901-906
        • Kazerouni N.N.
        • Currier B.
        • Malm L.
        • et al.
        Triple-marker prenatal screening program for chromosomal defects.
        Obstet Gynecol. 2009; 114: 50-58
        • Alexander G.R.
        • Himes J.H.
        • Kaufman R.B.
        • Mor J.
        • Kogan M.
        A United States national reference for fetal growth.
        Obstet Gynecol. 1996; 87: 163-168
        • American Medical Association
        International Classification of Diseases: ICD-9-CM 2008 Physician.
        9 ed. 2008
        • Boucoiran I.
        • Djemli A.
        • Taillefer C.
        • Rypens F.
        • Delvin E.
        • Audibert F.
        First-trimester prediction of birth weight.
        Am J Perinatol. 2013; 30: 665-672
        • Canini S.
        • Prefumo F.
        • Pastorino D.
        • et al.
        Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A.
        Fertil Steril. 2008; 89: 174-178
        • Kirkegaard I.
        • Uldbjerg N.
        • Oxvig C.
        Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview.
        Acta Obstet Gynecol Scand. 2010; 89: 1118-1125
        • Lawrence J.B.
        • Oxvig C.
        • Overgaard M.T.
        • et al.
        The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A.
        Proc Natl Acad Sci U S A. 1999; 96: 3149-3153
        • Giudice L.C.
        • Conover C.A.
        • Bale L.
        • et al.
        Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation.
        J Clin Endocrinol Metab. 2002; 87: 2359-2366
        • Qiu Q.
        • Bell M.
        • Lu X.
        • et al.
        Significance of IGFBP-4 in the development of fetal growth restriction.
        J Clin Endocrinol Metab. 2012; 97: E1429-E1439
        • Gagnon A.
        • Wilson R.D.
        • Audibert F.
        • et al.
        Obstetrical complications associated with abnormal maternal serum markers analytes.
        J Obstet Gynaecol Can. 2008; 30: 918-949
        • D’Antonio F.
        • Rijo C.
        • Thilaganathan B.
        • et al.
        Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complications.
        Prenat Diagn. 2013; 33: 839-847
        • Alberry M.
        • Soothill P.
        Management of fetal growth restriction.
        Arch Dis Child Fetal Neonatal Ed. 2007; 92: F62-F67